Regeneron Pharmaceuticals entered into a drug‑pricing agreement with the U.S. government that ties Medicaid drug pricing to benchmarks in other developed countries and aligns future U.S. medicine prices with those international levels. The agreement also allows the company’s cholesterol‑lowering drug Praluent to be purchased directly through TrumpRx.gov at a most‑favored‑nation price and grants Regeneron tariff relief for three years under a Department of Commerce arrangement.
Under the terms of the agreement, Regeneron will provide its newly approved gene therapy Otarmeni free of charge to eligible patients in the United States. Otarmeni, the first in‑vivo gene therapy for a rare form of genetic hearing loss, received accelerated approval from the U.S. Food and Drug Administration on April 23 2026.
Regeneron’s recent financial performance shows modest growth: Q4 2025 revenue was $3.9 billion, up 3% year‑over‑year, and full‑year 2025 revenue was $14.3 billion, up 1% from the prior year. In contrast, Q1 2025 revenue was $3.0 billion, down 4% from Q1 2024. The new pricing agreement may influence future revenue streams, particularly for Praluent, while the free‑access program for Otarmeni expands patient reach.
"For too long, American patients and taxpayers have shouldered a disproportionate share of the cost of biotechnology innovation, effectively subsidizing lower drug prices for other high‑income nations that have not been paying their fair share," said Dr. Leonard Schleifer. He added, "We hope that today's agreement, coupled with effective trade policy, will lead to closer equilibration of prices around the globe while preserving innovation and lowering prices for Americans." Dr. George Yancopoulos noted, "Our decision to provide Otarmeni for free in the United States serves to highlight our belief that the biopharmaceutical industry can be a genuine force for good in the world."
Analysts at TD Cowen said the deal removes tail risk and provides incremental impact on earnings, while analysts at Truist Securities and BMO Capital Markets highlighted the removal of potential regulatory uncertainty. The market reaction was mixed, reflecting investor caution about the pricing adjustments but confidence in the company’s strategic positioning.
The agreement signals a broader industry shift toward price transparency and international benchmarking. While the alignment of Medicaid pricing may reduce revenue from Praluent, tariff relief and the free‑access program for Otarmeni could offset some of the impact. The deal also expands patient reach for a rare genetic condition and positions Regeneron as a leader in access initiatives, potentially strengthening its long‑term competitive advantage.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.